This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Charlier, C. Articles by Plomteux, G. Search for Related Content PubMed PubMed Citation Articles by Charlier, C. Articles by Plomteux, G. Social Bookmarking                         What's this?

Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients.

University of Liège, Toxicology Laboratory, CHU Sart Tilman, Liège, Belgium

E. Pinto

M. Ansseau

University of Liège, Department of Psychiatry, CHU Sart Tilman, Liège, Belgium

G. Plomteux

University of Liège, Toxicology Laboratory, CHU Sart Tilman, Liège

The relationship between plasma drug level of venlafaxine and daily intake was studied in 89 major depressive inpatients. In addition, changes over time in severity were assessed weekly in a subgroup of 22 depressed patients using the Montgomery and Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression improvement scale. The results indicate a moderate correlation between daily doses and plasma concentrations, together with a higher relationship between improvement on the MADRS scale and concentration. Moreover, plasma concentrations (for venlafaxine and its predominant metabolite, O-desmethylvenlafaxine) up to 400 µg/l can be considered as effective, as already suggested in a previous study. No case of venlafaxine discontinuation occurred during the longitudinal study, and the incidence of adverse event, as estimated by the Target Emergent Symptoms and Side-effects scale, was low, suggesting that the drug is well tolerated for such plasma concentrations.

Key Words: clinical effects • compliance • depression • plasma concentration • venlafaxine

Journal of Psychopharmacology, Vol. 16, No. 4, 369-372 (2002)
DOI: 10.1177/026988110201600413


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Yoshida, H. Higuchi, M. Kamata, H. Takahashi, K. Inoue, T. Suzuki, K. Itoh, and N. Ozaki The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine J Psychopharmacol, August 1, 2007; 21(6): 650 - 656. [Abstract] [PDF]